TSVT — 2Seventy Bio Income Statement
0.000.00%
Last trade - 00:00- $231.93m
- $14.94m
- $100.39m
- 45
- 38
- 61
- 45
Annual income statement for 2Seventy Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 44.3 | 248 | 54.5 | 91.5 | 100 |
| Cost of Revenue | |||||
| Gross Profit | 41.3 | 243 | 52 | 74.9 | 83.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 385 | 386 | 368 | 355 | 338 |
| Operating Profit | -341 | -138 | -314 | -263 | -238 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -321 | -120 | -292 | -254 | -218 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -321 | -120 | -292 | -254 | -218 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -321 | -120 | -292 | -254 | -218 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -321 | -120 | -292 | -254 | -218 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -13.7 | -5.14 | -12 | -6.86 | -4 |
| Dividends per Share |